Short answer: GW0742 is an experimental PPAR-delta agonist, a close chemical relative of cardarine (GW501516). It has been studied in animals and cells, and in one anti-doping excretion study in people, but we found no published human trial of its effects. There is no researched dosage, so “GW0742 before and after” results online are anecdotal. In mice, a single injection of GW0742 or cardarine enlarged heart muscle cells within 24 hours (Wagner 2009). It is banned in sport as a PPAR-delta agonist.
Below: what GW0742 is, what the studies found, dosage and half-life, side effects including the heart findings, and how it compares with cardarine.
What is GW0742
Contrary to popular belief, GW0742 is not a new SARM, but just like Cardarine, belongs to a class of PPAR delta agonists.

When we look at the chemical structure of GW0742, we can see that there is only a small difference in one atom between the two compounds.
Their effects in the animal studies we checked were similar, though the compounds have not been compared in people. Claims online that GW0742 is “200 times stronger” than cardarine have no source we could find.
How Does It Work
GW0742 works just like any PPAR delta agonist out there. It basically has two jobs: Turning our fat into an energy source and increasing the oxidative capacity of our muscles.
This means that GW0742 should technically be amazing when it comes to increasing endurance in athletes.
Endurance with GW0742 has not been tested in people. For cardarine, endurance gains with training were shown in mice (Narkar 2008).
An animal study linked on the original version of this page reported anti-diabetic effects in animals. We found no published human trial of GW0742’s effects; the only human data we found are from an anti-doping study that gave volunteers a single dose to see how long it can be detected (Sobolevsky 2012).
GW0742 Legal Status
GW0742 is not an approved medicine anywhere we could find and is sold as a research chemical.
- Sport: WADA prohibits PPAR-delta agonists at all times (S4.4.1), naming GW1516 as an example (WADA 2026). GW0742 falls in the same class, and anti-doping labs can detect its breakdown products for up to 20 days after a single 15 mg dose (Sobolevsky 2012).
- Australia: the June 2026 Poisons Standard lists cardarine in Schedule 10, but we found no separate entry for GW0742 (Poisons Standard). The old version of this page said cardarine was Schedule 9; it is Schedule 10. Whether GW0742 is caught by another entry was not confirmed; see SARMs in Australia.
- Elsewhere: rules vary; see are SARMs legal.
GW0742 Benefits
All of the findings below come from animal or cell studies linked in the original version of this page; none has been shown in people.
Lowers Total Cholesterol
An animal study reported that GW0742 promoted reverse cholesterol transport, the route by which cholesterol is moved out of the body. For cardarine, human trials confirmed lipid effects: HDL up and LDL and triglycerides down (Olson 2012).
Reduces Inflammation in The Gut
Research in animals reported less gut inflammation with GW0742; this has not been studied in people.
Improves Lipid Profile
An animal study reported that small doses of GW0742 enhanced lipid metabolism in the heart.
That was an animal finding about heart lipid metabolism; whether GW0742 improves blood lipids in people has not been tested.
GW0742 Dosage, Cycle Length And Half Life
There is no researched human dose of GW0742. Animal studies used roughly 5–30 mg/kg, which cannot be converted into a human dose. The only human dosing we found was a single 15 mg dose in an anti-doping excretion study, which measured detection, not effects (Sobolevsky 2012).
The half-life in people is not established. The old version of this page assumed 24 hours “just like cardarine”, but cardarine’s human half-life has not been published either. In the excretion study, the unchanged drug was measurable only briefly, while its sulfone breakdown product was found for up to 20 days; GW0742 and its metabolites appeared in urine at about a tenth of the levels seen with cardarine (Sobolevsky 2012).
GW0742 Side Effects
Human side effects of GW0742 are not established. The main animal finding concerns the heart:
- In mice injected with GW0742 or cardarine, heart weight relative to body weight was higher after 24 hours, because heart muscle cells had enlarged; new blood vessel growth was seen after 5 hours. The researchers found no signs of pathological hypertrophy (no cell death, scarring or reduced heart function) and described the change as similar in some ways to exercise (Wagner 2009).
- What this means for people taking it for weeks is unknown. The old version of this page called it cardiomegaly; that is not what the study reported, but rapid heart growth from a drug is a reason for caution, not reassurance.

As a PPAR-delta agonist, GW0742 shares its target with cardarine, whose development was stopped after two-year animal studies found cancers in many organs (SOT 2009 abstracts).
Does GW0742 Cause Cancer
Unknown. We found no long-term cancer study of GW0742. Its close relative cardarine was tested in two-year studies: rats developed tumors in many organs at every dose tested and mice developed liver and stomach cancers, which is why GSK ended development in 2006 (SOT 2009 abstracts, GSK letter, 2013). The old version of this page called cardarine’s cancer risk a “myth”; that was wrong. Whether GW0742 carries the same risk has not been tested, and short animal studies at up to 30 mg/kg cannot answer a question about long-term cancer.
Where to Buy GW0742
GW0742 has very little research and an unresolved heart signal, so we don’t recommend it. It is also not sold by our partner shop. If you are comparing PPAR-delta compounds, cardarine at least has human trial data on blood lipids (and well-documented animal cancer findings); read the cardarine fact sheet and cardarine before and after first.
Whatever the compound, product quality is a real risk: in a JAMA test of products sold as SARMs, 39% contained a different unapproved drug, including GW501516 (Van Wagoner 2017).
GW0742 before and after: what to expect
We have no GW0742 before and after photos, and no study has measured body composition, fat loss or endurance in people taking it. Online before and after pictures are anecdotal, usually involve stacks with SARMs, and come with a diet. For PPAR-delta results that were measured, see the cardarine before and after page, which sets reader results against cardarine’s human trial data.
Conclusion
GW0742 is a cardarine-like PPAR-delta agonist with animal and cell data, a single-dose anti-doping study in people, and no published human trials of its effects. There is no researched dose or half-life, and in mice it enlarged heart muscle cells within a day. Its relative cardarine was abandoned over cancer findings in long-term animal studies, and GW0742 has never been tested for that. It is banned in sport. Compare compounds with human data in the SARMs database.
Frequently asked questions
What is GW0742?
A PPAR-delta agonist, not a SARMEvidence: Lab
An experimental PPAR-delta agonist chemically close to cardarine (GW501516). It is not a SARM and has been studied mainly in animals and cells.
What is the GW0742 dosage?
No researched human doseEvidence: Limited
There is no researched human dose. Animal studies used about 5–30 mg/kg, and one anti-doping study gave people a single 15 mg dose to measure detection, not effects.
Does GW0742 increase heart size?
In mice, yesEvidence: Animal
In mice, one injection of GW0742 or cardarine raised heart weight relative to body weight within 24 hours by enlarging heart muscle cells. No pathological hypertrophy was seen, but effects of longer use in people are unknown.
Is GW0742 better than cardarine?
Unknown; never compared in peopleEvidence: Limited
There is no human comparison, and claims that it is far stronger have no source. Cardarine has human data on blood lipids and documented animal cancer findings; GW0742 has neither human effect data nor long-term cancer studies.
What are GW0742 before and after results?
Not measured in any studyEvidence: User reports
No study has measured body changes with GW0742 in people. Before and after results online are anecdotal and usually involve stacks and dieting.
Is GW0742 banned in sport?
Yes, banned by WADAEvidence: Law
WADA prohibits PPAR-delta agonists at all times, and anti-doping labs can detect GW0742 metabolites for up to 20 days after a single 15 mg dose.
Sources
- Peroxisome proliferator-activated receptor beta stimulation induces rapid cardiac growth and angiogenesis via direct activation of calcineurin
- Detection of PPARδ agonists GW1516 and GW0742 and their metabolites in human urine
- Both the peroxisome proliferator-activated receptor delta agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal reabsorption of HDL-derived cholesterol
- GW0742, a selective PPAR-beta/delta agonist, contributes to the resolution of inflammation after gut ischemia/reperfusion injury
- Activation of receptors δ (PPARδ) by agonist (GW0742) may enhance lipid metabolism in heart both in vivo and in vitro
- Development of PPAR-agonist GW0742 as antidiabetic drug: study in animals
- AMPK and PPARdelta agonists are exercise mimetics
- Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome
- Rat carcinogenicity study with GW501516, a PPAR delta agonist (Geiger et al., abstract 895) and Mouse carcinogenicity study with GW501516, a PPAR delta agonist (Newsholme et al., abstract 896), The Toxicologist 2009
- Health Canada: GW501516 – Serious risks associated with use of unauthorized product (GSK letter, 24 May 2013)
- WADA: The Prohibited List (2026 List, in force from 1 January 2026)
- Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026 (F2026L00633)
- Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet
- PubChem: GW0742 (CID 9934458), names and synonyms